Review article
https://doi.org/10.2478/10004-1254-61-2010-2003
Genome Instability and Bleomicin Sensitivity Test
Mirta Milić
orcid.org/0000-0002-9837-7185
; Institut za medicinska istraživanja i medicinu rada, Zagreb, Hrvatska
Abstract
Estimation of individual susceptibility to mutagens is often a part of epidemiological studies monitoring the appearance of malignant disease in different populations. Genome exposure to mutagens can lead to DNA damage. The rate of damage depends on individual differences in response, which are usually associated with differences in DNA repair capacity. Cytogenetic studies have shown that the genome of tumour cells is less stable than normal cells and therefore accumulates more damage. Tumour patients show a higher
frequency of chromatid and chromosomal aberrations and a predisposition to certain types of tumours.
One of the common biomarkers used in monitoring tumour appearance and changed response to DNA damage is the bleomycin test. In its active form, bleomycin (glycopeptid) is a radiomimetic cytostatic that can damage the DNA molecule and cause multiple single and double strands. The bleomycin test is simple and inexpensive, and is based on scoring chromatid breaks in lymphocytes in vitro exposed to bleomycin during the late G2 phase of the cell cycle. This review looks into different factors that may
affect test results and discusses its wide implementation in studies of genome instability usually caused by a combination of factors.
Keywords
chromatid breaks; DNA damage repair; polymorphism; single strand breaks; translocations; tumour cells
Hrčak ID:
54058
URI
Publication date:
16.6.2010.
Visits: 2.130 *